Holen Sie sich die Stockscreener-App
104.15
1.30%
1.34
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CVS?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$102.81
Offen:
$103.69
24-Stunden-Volumen:
9.15M
Relative Volume:
1.12
Marktkapitalisierung:
$132.89B
Einnahmen:
$407.94B
Nettoeinkommen (Verlust:
$2.90B
KGV:
45.74
EPS:
2.2771
Netto-Cashflow:
$7.39B
1W Leistung:
-0.54%
1M Leistung:
+6.25%
6M Leistung:
+29.70%
1J Leistung:
+58.72%
1-Tages-Spanne:
$102.40
$105.46
1-Wochen-Bereich:
$101.78
$105.69
52-Wochen-Spanne:
$58.50
$106.15
Cvs Health Corp Stock (CVS) Company Profile
Firmenname
Cvs Health Corp
Sektor
Branche
Telefon
(401) 765-1500
Adresse
ONE CVS DR., WOONSOCKET
Compare CVS vs UNH, ELV, CI, HUM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
104.15 | 132.89B | 407.94B | 2.90B | 7.39B | 2.2771 |
UNH
Unitedhealth Group Inc
|
424.62 | 385.62B | 449.71B | 12.81B | 19.67B | 13.24 |
ELV
Elevance Health Inc
|
416.23 | 90.39B | 200.42B | 5.24B | 6.45B | 23.50 |
CI
Cigna Group
|
293.46 | 77.63B | 278.13B | 6.74B | 7.66B | 23.60 |
HUM
Humana Inc
|
392.22 | 47.09B | 137.20B | 1.15B | 1.27B | 9.3439 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-10-14 | Eingeleitet | Goldman | Buy |
| 2025-08-18 | Hochstufung | UBS | Neutral → Buy |
| 2025-08-14 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-12 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Edward Jones | Hold → Buy |
| 2024-12-03 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-11-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-10-04 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-30 | Eingeleitet | Robert W. Baird | Neutral |
| 2024-05-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-05-02 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-01 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-05-01 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-06 | Eingeleitet | Barclays | Equal Weight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-22 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-09-12 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-08-18 | Herabstufung | Edward Jones | Buy → Hold |
| 2023-05-26 | Eingeleitet | Piper Sandler | Overweight |
| 2023-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-06-17 | Eingeleitet | Loop Capital | Buy |
| 2022-05-27 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2022-03-29 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-12-14 | Eingeleitet | Goldman | Buy |
| 2021-12-01 | Eingeleitet | Seaport Research Partners | Buy |
| 2021-05-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-01-08 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-17 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-01 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-05-14 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-09-27 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Buy |
| 2019-06-05 | Hochstufung | Standpoint Research | Hold → Buy |
| 2019-04-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-04-18 | Eingeleitet | Guggenheim | Buy |
| 2019-04-15 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2019-04-10 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-13 | Eingeleitet | Bernstein | Outperform |
| 2019-02-20 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-18 | Eingeleitet | Barclays | Overweight |
| 2018-11-29 | Fortgesetzt | Goldman | Neutral |
| 2018-11-28 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-26 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2018-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-02-27 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-02-13 | Bestätigt | Citigroup | Neutral |
Alle ansehen
Cvs Health Corp Aktie (CVS) Neueste Nachrichten
CVS Health stock holds steady on its pharmacy scale - ad-hoc-news.de
CVS Health Corporation Plans Quarterly Dividend of $0.67 (NYSE:CVS) - MarketBeat
CVS Health Corp. stock outperforms competitors on strong trading day - MarketWatch
CNO stock holds steady as the insurer keeps its focus on benefit lines - ad-hoc-news.de
Healthcare Stocks Shine Ahead of Q2 2026 Earnings, Including CVS (CVS) - GuruFocus
CVS Announces $0.665 Quarterly Dividend, Consistent with Previou - GuruFocus
What to Expect From CVS Health's Q2 2026 Earnings Report - Barchart.com
CVS Health declares quarterly dividend of $0.665 per share - Investing.com
CVS Health declares quarterly dividend of $0.665 per share By Investing.com - Investing.com Canada
CVS Health schedules Aug. 3 payout for $0.665 dividend - Stock Titan
Pharmacy Benefit Manager Suit Shows Trump Admin's Keenness For Deals - Seeking Alpha
Sumitomo Mitsui Trust Group Inc. Decreases Stock Holdings in CVS Health Corporation $CVS - MarketBeat
CVS Health (CVS) Focuses on AI to Enhance Profitability Amid Ris - GuruFocus
CVS Health Corp. stock underperforms Thursday when compared to competitors - MarketWatch
CVS Secures Major Settlement Amid Omnicare Allegations - GuruFocus
CVS Maintains Outperform Rating -- Price Target Raised to $113 - GuruFocus
CVS Stock Quote Price and Forecast - CNN
CVS Price Today: CVS HEALTH CORPORATION Stock Price, Quote & Chart - MEXC
Aetna provides $300K to Christian Hospital Foundation to support food pharmacy program - Drug Store News
CVS CEO says Aetna has a handle on medical costs in advance of Q2 earnings - Yahoo Finance
CVS Health Corp. balances retail pressures and healthcare growth - ad-hoc-news.de
HIV Is Now a Manageable Chronic ConditionHow CVS Specialty Helps Patients Start and Stay on Treatment - Yahoo Finance
CVS Health Blood Pressure Monitor by CVS Health Corp.pharmacy brand quietly expands home diagnost - Ad-hoc-news.de
CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance Australia
Obamacare Premiums Could Jump 14% in 2027 As Insurers Warn Rising Medical Costs are Driving Rates Higher - Benzinga
Why Is CVS Health (NYSE:CVS) in the S&P 500 Healthcare Index? - Kalkine Media
CVS Health Corp. focuses on pharmacy and health services as investors watch long-term strategy - ad-hoc-news.de
CVS Health outlook and strategy as a diversified U.S. healthcare player - AD HOC NEWS
Cantor Fitzgerald raises CVS Health stock price target on margins By Investing.com - Investing.com Canada
CVS Health (NYSE:CVS) Rally Faces A Healthcare Test - Kalkine Media
CVS Health (NYSE:CVS) Upgraded at Wall Street Zen - MarketBeat
CVS Maintained by Cantor Fitzgerald -- Price Target Raised to $1 - GuruFocus
Burney Co. Reduces Stock Position in CVS Health Corporation $CVS - MarketBeat
CVS Health (NYSE:CVS) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat
CVS Health: Thank You! Mews at St. Mary Affordable Housing Grand OpeningWilliamstown, New Jersey - Morningstar
Cantor Fitzgerald raises CVS Health stock price target on margins - Investing.com
CVS Health (CVS) Settles Medicaid Claims As Omnicare Sale Wins Court Approval - Yahoo Finance
CVS Health’s SWOT analysis: stock faces margin recovery test - Investing.com
CVS Health’s SWOT analysis: stock faces margin recovery test By Investing.com - Investing.com Canada
2 Big Dividends on Sale as Warsh Targets Inflation and Yields Up to 11.9% - Investing.com
CVS Health Corp. steadies its strategy as retail and pharmacy pressures persist - ad-hoc-news.de
Why Are CVS Health (NYSE:CVS) Earnings Making S&P 500 News? - Kalkine Media
CVS To Pay $36.5M To Settle States' Insulin FCA Suits - Law360
Omnicare, CVS Health reach $440 million settlement in senior living prescription fraud case - McKnight's Senior Living
CVS Health Corp. stock underperforms Monday when compared to competitors - MarketWatch
Are You Looking for a Top Momentum Pick? Why CVS Health (CVS) is a Great Choice - Yahoo Finance
CVS Health to discuss Q2 2026 results on Aug. 5 - Stock Titan
CVS Health: The Surprising Healthcare Outlier (NYSE:CVS) - Seeking Alpha
CVS Health Corporation $CVS Holdings Reduced by World Investment Advisors - MarketBeat
QRG Capital Management Inc. Has $7 Million Stock Holdings in CVS Health Corporation $CVS - MarketBeat
CVS Health Disposable Face Masks from CVS Health Corp.Everyday protection in US stores - Ad-hoc-news.de
Finanzdaten der Cvs Health Corp-Aktie (CVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.99%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):